$RNN Rexhan said it signed a collaboration and licensing agreement with BioSense Global, a privately held company with offices in New Jersey and China, to exclusively advance the development and commercialization of RX-3117 in Greater China. RX-3117 is Rexahn's investigational oral, small molecule nucleoside compound under evaluation for first-line pancreatic cancer and advanced or metastatic bladder cancer.